as mentioned kytril is through HLR, and uses granisetron. Granisetron is currently not under patent protection hence open to competition so basically sales will fall because of it. Moreover, it is much more sought after to prevent the onset CINV versus controlling it once it gets there. APPA chose this compound because it didnt have to pay HLR royalties to use as its patent was up, so im guessing they didnt pay anything to HLR. This new formulation also makes it the only drug of its kind which helps prevent onset of CINV and blocks it also once it gets there. Additionally it lasts for 5 days versus aloxi which lasts for 3 days. Moreover its administered much more easily than aloxi as well, it has numerous plus's going for it. There is a reason the CEO has almost 13 million shares!
oh and one more thing this new formulation will be under patent protection as it looks after two different targets for CINV, you can file a utility patent for that which i am sure APPA has done already or is in the process of getting.
Market Data 
Markets 
AI
